Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

被引：32
|
作者：
Ligumsky, Hagai [1 ,6 ]
Dor, Herut [6 ]
Etan, Tal [1 ]
Golomb, Inbal [1 ,6 ]
Nikolaevski-Berlin, Alla [1 ]
Greenberg, Inbal [6 ]
Halperin, Tamar [2 ]
Angel, Yoel [3 ,6 ]
Henig, Oryan [4 ,6 ]
Spitzer, Avishay [1 ,6 ,7 ]
Slobodkin, Marina [5 ,6 ]
Wolf, Ido [1 ,6 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Oncol Div, IL-6423906 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Human Immunodeficiency Virus Lab, IL-6423906 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Anasthesia Pain & Intens Care, IL-6423906 Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Infect Dis & Infect Control, IL-6423906 Tel Aviv, Israel
[5] Tel Aviv Sourasky Med Ctr, Dept Internal Med D, IL-6423906 Tel Aviv, Israel
[6] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[7] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(21)00715-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：193 / 195
页数：3
相关论文
共 50 条
  • [21] Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
    Louise Murdoch
    Karen Quan
    James A. Baber
    Agnes W. Y. Ho
    Ying Zhang
    Xia Xu
    Claire Lu
    David Cooper
    Kenneth Koury
    Stephen P. Lockhart
    Annaliesa S. Anderson
    Özlem Türeci
    Uğur Şahin
    Kena A. Swanson
    William C. Gruber
    Nicholas Kitchin
    Infectious Diseases and Therapy, 2023, 12 : 2241 - 2258
  • [22] Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
    Murdoch, Louise
    Quan, Karen
    Baber, James A.
    Ho, Agnes W. Y.
    Zhang, Ying
    Xu, Xia
    Lu, Claire
    Cooper, David
    Koury, Kenneth
    Lockhart, Stephen P.
    Anderson, Annaliesa S.
    Tuereci, Ozlem
    Sahin, Ugur
    Swanson, Kena A.
    Gruber, William C.
    Kitchin, Nicholas
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (09) : 2241 - 2258
  • [23] Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study
    Diamantopoulos, Panagiotis T.
    Stafylidis, Christos
    Vlachopoulou, Dimitra
    Kontandreopoulou, Christina-Nefeli
    Giannakopoulou, Nefeli
    Vardaka, Maria
    Mpouhla, Anthi
    Mastrogianni, Elpida
    Variami, Eleni
    Galanopoulos, Athanasios
    Pappa, Vasiliki
    Psichogiou, Mina
    Hatzakis, Angelos
    Viniou, Nora-Athina
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [24] Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs
    Cristaudo, A.
    Graceffa, D.
    Pimpinelli, F.
    Sperati, F.
    Spoletini, G.
    Bonifati, C.
    Pellini, R.
    Lora, V.
    Pontone, M.
    Di Bella, O.
    Bracco, D.
    Morrone, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (04) : E266 - E268
  • [25] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Polack, Fernando P.
    Thomas, Stephen J.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Perez, John L.
    Perez Marc, Gonzalo
    Moreira, Edson D.
    Zerbini, Cristiano
    Bailey, Ruth
    Swanson, Kena A.
    Roychoudhury, Satrajit
    Koury, Kenneth
    Li, Ping
    Kalina, Warren V.
    Cooper, David
    Frenck, Robert W., Jr.
    Hammitt, Laura L.
    Tureci, Ozlem
    Nell, Haylene
    Schaefer, Axel
    Unal, Serhat
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) : 2603 - 2615
  • [26] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Skowronski, Danuta M.
    De Serres, Gaston
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) : 1576 - 1577
  • [27] Efficacy and toxicity of BNT162b2 vaccine in cancer patients
    Ben-Aharon, I.
    Waldhorn, I.
    Holland, R.
    Peer, A.
    Halberthal, M.
    Goshen-Lago, T. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1130 - S1130
  • [28] Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
    Frenck, Robert W., Jr.
    Klein, Nicola P.
    Kitchin, Nicholas
    Gurtman, Alejandra
    Absalon, Judith
    Lockhart, Stephen
    Perez, John L.
    Walter, Emmanuel B.
    Senders, Shelly
    Bailey, Ruth
    Swanson, Kena A.
    Ma, Hua
    Xu, Xia
    Koury, Kenneth
    Kalina, Warren V.
    Cooper, David
    Jennings, Timothy
    Brandon, Donald M.
    Thomas, Stephen J.
    Tureci, Ozlem
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03) : 239 - 250
  • [29] Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency
    Milota, Tomas
    Smetanova, Jitka
    Skotnicova, Aneta
    Rataj, Michal
    Lastovicka, Jan
    Zelena, Hana
    Parackova, Zuzana
    Fejtkova, Martina
    Kanderova, Veronika
    Fronkova, Eva
    Rejlova, Katerina
    Sediva, Anna
    Kalina, Tomas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (01) : 306 - +
  • [30] Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
    Rocco Capuano
    Manuela Altieri
    Miriana Conte
    Alvino Bisecco
    Alessandro d’Ambrosio
    Giovanna Donnarumma
    Elena Grimaldi
    Nicola Coppola
    Nicola Medici
    Massimiliano Galdiero
    Gioacchino Tedeschi
    Antonio Gallo
    Journal of Neurology, 2022, 269 : 6185 - 6192
12345